Search

Astellas Pharma Inc

Open

1,688 1.38

Overview

Share price change

24h

Current

Min

1666

Max

1697

Key metrics

By Trading Economics

Income

-48B

-33B

Sales

-49B

373B

P/E

Sector Avg

620.75

EPS

4.33

Profit margin

-8.916

EBITDA

-62B

4.2B

Dividends

By Dow Jones

Next Earnings

1 Aug 2024

Next Ex Dividend date

26 Sept 2024

Market Stats

By TradingEconomics

Market Cap

120B

3T

Previous open

1686.62

Previous close

1688

News Sentiment

By Acuity

49%

51%

Astellas Pharma Inc Chart

Related News

1 May 2024, 16:54 UTC

Major Market Movers

Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences

7 Aug 2023, 14:26 UTC

Major Market Movers

Poseida Therapeutics Shares Leap on Astellas Investments

28 Aug 2023, 05:18 UTC

Acquisitions, Mergers, Takeovers

Novartis: Mycamine Is Antifungal Treatment

28 Aug 2023, 05:16 UTC

Acquisitions, Mergers, Takeovers

Novartis: Sandoz Completes Acquisition of Mycamine Brand From Astellas

Astellas Pharma Inc Forecast

Sentiment

By Acuity

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Astellas Pharma Inc

Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.